Atherosclerosis
Volume 205, Issue 1 , Pages 186-191 , July 2009

PPARgamma Promoter Polymorphisms and Acute Coronary Syndrome

  • L. Evangelisti

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Corresponding Author InformationCorresponding author at: Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. Tel.: +39 055 7949420; fax: +39 055 7949418.
    • ,
  • M. Attanasio

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • ,
  • L. Lucarini

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • ,
  • F. Sofi

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • ,
  • R. Marcucci

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • ,
  • C. Giglioli

      Affiliations

    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • ,
  • S. Valente

      Affiliations

    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • ,
  • GF. Gensini

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • Centro S. Maria agli Ulivi, Fondazione Don Carlo Gnocchi, Onlus, IRCCS, Florence, Italy
    • ,
  • R. Abbate

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
    • ,
  • G. Pepe

      Affiliations

    • Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Center of the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Disease to Develop Novel Therapies, University of Florence, Italy
    • Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy

Received 1 July 2008 ,Revised 22 October 2008 ,Accepted 9 November 2008.

References 

  1. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201–2207
  2. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR gene. J Biol Chem. 1997;272:18779–18789
  3. Fajas L, Fruchart JC, Auwerx J. PPAR 3 mRNA: a distinct PPAR mRNA subtype transcribed from an independent promoter. FEBS Lett. 1998;438:55–60
  4. Sundvold H, Sigbjørn L. Identification of a novel peroxisome proliferator-activated receptor PPAR promoter in man and transactivation by the nuclear receptor ROR 1. Biochem Biophys Res Commun. 2001;287:383–390
  5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224–1234
  6. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARgamma in humans. Mol Genet Metab. 2004;83(1–2):93–102
  7. Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000;106:1221–1228
  8. Tontonoz P, Nagy L, Alvarez J, Thomazy V, Evan R. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93(2):241–252
  9. Nagy L, Tontonoz P, Alvarez J, Chen H, Evans R. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93(2):229–240
  10. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83(11):1097–1103
  11. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82
  12. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86
  13. Jackson SM, Farhad Parhami, Xiao-Ping Xi, et al. Demer. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19(9):2094–2104
  14. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85(5):394–402
  15. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101(3):235–238
  16. Meirhaeghe A, Fajas L, Helbecque N, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet. 1998;7(3):435–440
  17. Evans D, de Heer J, Hagemann C, et al. Association between the PRO12ALA and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001;109(3):151–154
  18. Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes. 2001;50(4):886–890
  19. Frederiksen L, Brodbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002;87(8):3989–3992
  20. Masud S, Ye S SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 2003;40(10):773–780
  21. Ridker PM, Cook NR, Cheng S, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARg2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23(5):859–863
  22. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161T polymorphism and coronary artery disease. Cardiovasc Res. 1999;44(3):588–594
  23. Meirhaeghe A, Fajas L, Gouilleux F, et al. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol. 2003;23(2):289–294
  24. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes. 2005;54(10):3043–3048
  25. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA Guideline Update for the Management of Patients with Unstable Angina and Non-STsegment Elevation of Myocardial Infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  26. Cifkova R, Erdine S, Fagard R, et al. ESH/ESC hypertension guidelines committee. Practice guidelines for primary care physicians: 2003 ESH/ESC Hypertension guidelines. Hypertension. 2003;21:1779–1786
  27. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:5–20.
  28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment in Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.
  29. Sofi F, Vecchio S, Giuliani G, et al. Dietary habits, lifestyle and cardiovascular risk factors in a clinically healthy Italian population: the “Florence” diet is not Mediterranean. Eur J Clin Nutr. 2005;59:584–591
  30. Giusti B, Lucarini L, Pietroni V, et al. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Ann Neurol. 2005;58(3):400–410
  31. Francis NJ, Kingston RE. Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol. 2001;2:409–421
  32. Chao TH, Li YH, Chen JH, et al. The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci. 2004;107(5):461–466
  33. Pischon T, Pai JK, Manson JE, et al. Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol. 2005;25(August):1654–1658
  34. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag. 2008;4:427–436
  35. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARg locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol. 2004;24:2403–2407
  36. Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol. 2006;29:300–304
  37. Wolford JK, Yeatts AK, Dhanjal SK, et al. Sequence variation in PPARg may underlie differential response to troglitazone. Diabetes. 2005;54:3319–3325

PII: S0021-9150(08)00790-9

doi: 10.1016/j.atherosclerosis.2008.11.009

Atherosclerosis
Volume 205, Issue 1 , Pages 186-191 , July 2009

Article Tools